Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in Acta Neurol Scand

Retrieve available abstracts of 60 articles:
HTML format
Text format



Single Articles


    November 2018
  1. PIRTTISALO AL, Soilu-Hanninen M, Sipila JOT
    Multiple sclerosis epidemiology in Finland: regional differences and high incidence.
    Acta Neurol Scand. 2018 Nov 27. doi: 10.1111/ane.13057.
    PubMed     Text format     Abstract available


  2. DAL-BIANCO A, Wenhoda F, Rommer PS, Weber M, et al
    Do Elevated Autoantibodies in Patients With Multiple Sclerosis Matter ?
    Acta Neurol Scand. 2018 Nov 17. doi: 10.1111/ane.13054.
    PubMed     Text format     Abstract available


  3. MELBYE P, Olsson A, Hansen TH, Sondergaard HB, et al
    Short-Chain Fatty Acids and Gut Microbiota in Multiple Sclerosis.
    Acta Neurol Scand. 2018 Nov 14. doi: 10.1111/ane.13045.
    PubMed     Text format     Abstract available


  4. STEENHOF M, Nielsen NM, Stenager E, Kyvik K, et al
    Distribution of disease courses in familial versus sporadic multiple sclerosis.
    Acta Neurol Scand. 2018 Nov 9. doi: 10.1111/ane.13044.
    PubMed     Text format     Abstract available


    October 2018
  5. HOLMOY T, Rosjo E, Zetterberg H, Blennow K, et al
    Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
    Acta Neurol Scand. 2018 Oct 13. doi: 10.1111/ane.13037.
    PubMed     Text format     Abstract available


  6. BAYART JL, Muls N, van Pesch V
    Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?
    Acta Neurol Scand. 2018;138:352-358.
    PubMed     Text format     Abstract available


    August 2018
  7. HAGHIGHI S, Forsmark S, Carlsson A, Nilsson MKL, et al
    Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.
    Acta Neurol Scand. 2018 Aug 22. doi: 10.1111/ane.13007.
    PubMed     Text format     Abstract available


  8. BAUMGARTNER A, Frings L, Schiller F, Stich O, et al
    Regional neuronal activity in patients with relapsing remitting multiple sclerosis.
    Acta Neurol Scand. 2018 Aug 8. doi: 10.1111/ane.13012.
    PubMed     Text format     Abstract available


    July 2018
  9. MURLEY C, Yang F, Gyllensten H, Alexanderson K, et al
    Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 24. doi: 10.1111/ane.13001.
    PubMed     Text format     Abstract available


  10. ROMEO MAL, Martinelli V, Dalla Costa G, Colombo B, et al
    Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.
    Acta Neurol Scand. 2018 Jul 22. doi: 10.1111/ane.12999.
    PubMed     Text format     Abstract available


  11. GAVRILOV YV, Shkilnyuk GG, Valko PO, Stolyarov ID, et al
    Validation of the Russian version of the Fatigue Impact Scale and Fatigue Severity Scale in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Jul 9. doi: 10.1111/ane.12993.
    PubMed     Text format     Abstract available


  12. CANDELIERE MERLICCO A, Gabaldon Torres L, Villaverde Gonzalez R, Fernandez Romero I, et al
    Transorbital ultrasonography for measuring optic nerve atrophy in multiple sclerosis.
    Acta Neurol Scand. 2018 Jul 2. doi: 10.1111/ane.12976.
    PubMed     Text format     Abstract available


    June 2018
  13. DALE GH, Svendsen KB, Gjelstrup MC, Christensen T, et al
    Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region.
    Acta Neurol Scand. 2018;137:582-588.
    PubMed     Text format     Abstract available


    May 2018
  14. BERNTSSON SG, Kristoffersson A, Bostrom I, Feresiadou A, et al
    Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
    Acta Neurol Scand. 2018 May 24. doi: 10.1111/ane.12963.
    PubMed     Text format     Abstract available


  15. SEBASTIAO E, Motl RW
    Body mass index and cardiorespiratory fitness in persons with multiple sclerosis.
    Acta Neurol Scand. 2018 May 11. doi: 10.1111/ane.12959.
    PubMed     Text format     Abstract available


  16. ABDOLLAHPOUR I, Nedjat S, Mansournia MA, Eckert S, et al
    Infectious exposure, antibiotic use, and multiple sclerosis: A population-based incident case-control study.
    Acta Neurol Scand. 2018 May 9. doi: 10.1111/ane.12958.
    PubMed     Text format     Abstract available


    March 2018
  17. HEYDARPOUR P, Manouchehrinia A, Beiki O, Mousavi SE, et al
    Smoking and worsening disability in multiple sclerosis: A meta-analysis.
    Acta Neurol Scand. 2018 Mar 15. doi: 10.1111/ane.12916.
    PubMed     Text format     Abstract available


  18. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.
    Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921.
    PubMed     Text format     Abstract available


  19. RAHMANZADEH R, Weber MS, Bruck W, Navardi S, et al
    B cells in multiple sclerosis therapy-A comprehensive review.
    Acta Neurol Scand. 2018 Mar 7. doi: 10.1111/ane.12915.
    PubMed     Text format     Abstract available


    February 2018
  20. MANI A, Chohedri E, Ravanfar P, Mowla A, et al
    Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
    Acta Neurol Scand. 2018 Feb 7. doi: 10.1111/ane.12904.
    PubMed     Text format     Abstract available


  21. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Real-life clinical use of natalizumab and fingolimod in Austria.
    Acta Neurol Scand. 2018;137:181-187.
    PubMed     Text format     Abstract available


  22. NICKEL S, von dem Knesebeck O, Kofahl C
    Self-assessments and determinants of HRQoL in a German MS population.
    Acta Neurol Scand. 2018;137:174-180.
    PubMed     Text format     Abstract available


    January 2018
  23. MESCHERIAKOVA JY, Hintzen RQ
    No excess of autoimmune diseases in multiple sclerosis families from the Netherlands.
    Acta Neurol Scand. 2018 Jan 7. doi: 10.1111/ane.12896.
    PubMed     Text format     Abstract available


  24. RORSMAN I, Petersen C, Nilsson PC
    Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Acta Neurol Scand. 2018;137:117-124.
    PubMed     Text format     Abstract available


    December 2017
  25. OLSSON A, Oturai AB, Sondergaard HB, Sellebjerg F, et al
    Bone microarchitecture and bone mineral density in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 21. doi: 10.1111/ane.12884.
    PubMed     Text format     Abstract available


  26. ZECCA C, Antozzi CG, Torri Clerici V, Ferrazzini M, et al
    Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12882.
    PubMed     Text format     Abstract available


  27. HEESEN C, Haase R, Melzig S, Poettgen J, et al
    Perceptions on the value of bodily functions in multiple sclerosis.
    Acta Neurol Scand. 2017 Dec 3. doi: 10.1111/ane.12881.
    PubMed     Text format     Abstract available


    November 2017
  28. ZETTERBERG H
    Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:15-17.
    PubMed     Text format     Abstract available


  29. LYCKE J
    Trials of antivirals in the treatment of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:45-48.
    PubMed     Text format     Abstract available


  30. CELIUS EG
    Infections in patients with multiple sclerosis: Implications for disease-modifying therapy.
    Acta Neurol Scand. 2017;136 Suppl 201:34-36.
    PubMed     Text format     Abstract available


  31. WEKERLE H
    Nature, nurture, and microbes: The development of multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:22-25.
    PubMed     Text format     Abstract available


  32. FREDERIKSEN JL, Topsoe Mailand M
    Vaccines and multiple sclerosis.
    Acta Neurol Scand. 2017;136 Suppl 201:49-51.
    PubMed     Text format     Abstract available


  33. WENDEL-HAGA M, Celius EG
    Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
    Acta Neurol Scand. 2017;136 Suppl 201:26-30.
    PubMed     Text format     Abstract available


    August 2017
  34. WALLIN MT, Culpepper WJ, Maloni H, Kurtzke JF, et al
    The Gulf War era multiple sclerosis cohort: 3. Early clinical features.
    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12810.
    PubMed     Text format     Abstract available


    July 2017
  35. ANDERSEN O, Hildeman A, Longfils M, Tedeholm H, et al
    Diffusion tensor imaging in multiple sclerosis at different final outcomes.
    Acta Neurol Scand. 2017 Jul 25. doi: 10.1111/ane.12797.
    PubMed     Text format     Abstract available


  36. CAMBRON M, Hadhoum N, Duhin E, Lacour A, et al
    JCV serology in time: 3 years of follow-up.
    Acta Neurol Scand. 2017;136:54-58.
    PubMed     Text format     Abstract available


    May 2017
  37. MENTIS AA, Dardiotis E, Grigoriadis N, Petinaki E, et al
    Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation.
    Acta Neurol Scand. 2017 May 23. doi: 10.1111/ane.12775.
    PubMed     Text format     Abstract available


    April 2017
  38. MARTINELLI V, Dalla Costa G, Messina MJ, Di Maggio G, et al
    Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.
    Acta Neurol Scand. 2017 Apr 9. doi: 10.1111/ane.12761.
    PubMed     Text format     Abstract available


    March 2017
  39. ELKJAER ML, Molnar T, Illes Z
    Teriflunomide for multiple sclerosis in real-world setting.
    Acta Neurol Scand. 2017 Mar 20. doi: 10.1111/ane.12755.
    PubMed     Text format     Abstract available


  40. SCHNEIDER R, Bellenberg B, Kleiter I, Gold R, et al
    Cervical cord and ventricle affection in neuromyelitis optica.
    Acta Neurol Scand. 2017;135:324-331.
    PubMed     Text format     Abstract available


    February 2017
  41. ENSARI I, Pilutti LA, Motl RW
    Depressive symptomology in multiple sclerosis: Disability, cardiorespiratory fitness and heart rate variability.
    Acta Neurol Scand. 2017 Feb 26. doi: 10.1111/ane.12748.
    PubMed     Text format     Abstract available


    January 2017
  42. LUNDELL H, Svolgaard O, Dogonowski AM, Romme Christensen J, et al
    Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis.
    Acta Neurol Scand. 2017 Jan 10. doi: 10.1111/ane.12729.
    PubMed     Text format     Abstract available


  43. VOLDSGAARD A, Koch-Henriksen N, Magyari M, Sellebjerg F, et al
    Early safety and efficacy of fingolimod treatment in Denmark.
    Acta Neurol Scand. 2017;135:129-133.
    PubMed     Text format     Abstract available


    December 2016
  44. KARAMYAN A, Brandtner H, Grinzinger S, Chroust V, et al
    Causes of death in critically ill multiple sclerosis patients.
    Acta Neurol Scand. 2016 Dec 23. doi: 10.1111/ane.12724.
    PubMed     Text format     Abstract available


  45. TANASESCU R, Midgley A, Robins RA, Constantinescu CS, et al
    Decreased interferon-beta induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.
    Acta Neurol Scand. 2016 Dec 5. doi: 10.1111/ane.12715.
    PubMed     Text format     Abstract available


  46. D'HOOGHE MB, Haentjens P, Van Remoortel A, De Keyser J, et al
    Self-reported levels of education and disability progression in multiple sclerosis.
    Acta Neurol Scand. 2016;134:414-419.
    PubMed     Text format     Abstract available


    November 2016
  47. PEARSON JF, Alla S, Clarke G, Mason DF, et al
    Multiple Sclerosis impact on employment and income in New Zealand.
    Acta Neurol Scand. 2016 Nov 28. doi: 10.1111/ane.12714.
    PubMed     Text format     Abstract available


  48. SOELBERG SORENSEN P
    Safety concerns and risk management of multiple sclerosis therapies.
    Acta Neurol Scand. 2016 Nov 27. doi: 10.1111/ane.12712.
    PubMed     Text format     Abstract available


    October 2016
  49. ZETTL UK, Schreiber H, Bauer-Steinhusen U, Glaser T, et al
    Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 30. doi: 10.1111/ane.12705.
    PubMed     Text format     Abstract available


  50. GOUVEIA A, Dias SP, Santos T, Rocha H, et al
    Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.
    Acta Neurol Scand. 2016 Oct 24. doi: 10.1111/ane.12702.
    PubMed     Text format     Abstract available


    September 2016
  51. PUZ P, Lasek-Bal A, Radecka P
    Transcranial sonography of subcortical structures in patients with multiple sclerosis.
    Acta Neurol Scand. 2016 Sep 18. doi: 10.1111/ane.12689.
    PubMed     Text format     Abstract available


  52. ROMMER PS, Suhnel A, Konig N, Zettl UK, et al
    Coping with multiple sclerosis-the role of social support.
    Acta Neurol Scand. 2016 Sep 12. doi: 10.1111/ane.12673.
    PubMed     Text format     Abstract available


  53. MUCKSCHEL M, Beste C, Ziemssen T
    Immunomodulatory treatments and cognition in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:55-9.
    PubMed     Text format     Abstract available


  54. BERGER T
    Immunological processes related to cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:34-8.
    PubMed     Text format     Abstract available


  55. PAUL F
    Pathology and MRI: exploring cognitive impairment in MS.
    Acta Neurol Scand. 2016;134 Suppl 200:24-33.
    PubMed     Text format     Abstract available


  56. PORTACCIO E
    Differential diagnosis, discerning depression from cognition.
    Acta Neurol Scand. 2016;134 Suppl 200:14-8.
    PubMed     Text format     Abstract available


  57. HAMALAINEN P, Rosti-Otajarvi E
    Cognitive impairment in MS: rehabilitation approaches.
    Acta Neurol Scand. 2016;134 Suppl 200:8-13.
    PubMed     Text format     Abstract available


  58. VAN ETTINGER-VEENSTRA H
    Cumulative evidence for MS as a neural network disconnection syndrome consistent with cognitive impairment mechanisms and the confounding role of fatigue and depression-outlook from the Fourth Nordic MS symposium.
    Acta Neurol Scand. 2016;134 Suppl 200:4-7.
    PubMed     Text format     Abstract available


    May 2016
  59. KOLASA M, Hagman S, Verkkoniemi-Ahola A, Airas L, et al
    Anti-JC virus seroprevalence in a Finnish MS cohort.
    Acta Neurol Scand. 2016;133:391-7.
    PubMed     Text format     Abstract available


    April 2016
  60. HOLMOY T, Esbensen QY, Torkildsen O, Wergeland S, et al
    WT1 and interferon-beta-vitamin D association in MS: a longitudinal study.
    Acta Neurol Scand. 2016;133:309-12.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: